CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


PamrevlumabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug961 Follow-up at 14 days Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF), in Hospitalized Patients With Acute COVID-19 Disease

This is a Phase 2 trial to evaluate the efficacy and safety of intravenous (IV) infusions of pamrevlumab as compared to placebo in hospitalized subjects with acute COVID-19 disease.

NCT04432298 COVID-19 Drug: Pamrevlumab Drug: Placebo

Primary Outcomes

Measure: Proportion of subjects who never received mechanical ventilation and/or ECMO and alive

Time: Baseline to Day 28

Secondary Outcomes

Measure: Proportion of subjects alive, discharged home, and not on supplemental oxygen

Time: Baseline to Day 28

Measure: Time to recovery based on a Modified 8-Point Ordinal Scale

Time: Baseline to Day 28

Measure: Days in ICU/CCU (either on or off mechanical ventilation and/or ECMO)

Time: Baseline to Day 28

Measure: Days on mechanical ventilation and/or ECMO

Time: Baseline to Day 28

Measure: Time to death from any cause

Time: Baseline to Day 28

Measure: Changes in PaO2/FiO2 ratio, both as categorical and continuous variable

Time: Baseline to Day 28

Measure: Change in (non-invasive) oxygen supplementation requirements

Time: Baseline to Day 28


No related HPO nodes (Using clinical trials)